Cost-effectiveness of a cardiovascular disease risk reduction program aimed at financially vulnerable women: the Massachusetts WISEWOMAN project.

Eric A Finkelstein, Philip J Troped, Julie C Will, Ruth Palombo
{"title":"Cost-effectiveness of a cardiovascular disease risk reduction program aimed at financially vulnerable women: the Massachusetts WISEWOMAN project.","authors":"Eric A Finkelstein,&nbsp;Philip J Troped,&nbsp;Julie C Will,&nbsp;Ruth Palombo","doi":"10.1089/152460902760277877","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The Massachusetts WISEWOMAN Project is a cardiovascular disease (CVD) risk reduction program targeting older uninsured and underinsured women. The cost-effectiveness of providing CVD screening and enhanced lifestyle interventions (EI), compared with providing CVD screening and a minimum intervention (MI), was assessed at five El and six MI healthcare sites.</p><p><strong>Methods: </strong>Cost calculations were based on data collected during screenings and intervention activities conducted with 1586 women in 1996. Risk factor data, including cholesterol and blood pressure measures, were used to create a summary effectiveness outcome, the 10-year probability of developing coronary heart disease (CHD). The cost-effectiveness ratio of the EI, compared with the MI, was calculated by dividing the incremental cost of the EI by the incremental effectiveness of the EI.</p><p><strong>Results: </strong>The incremental cost of the EI was $191. During the 1-year study period, the 10-year probability of CHD decreased from 9.4% to 9.2% in the MI group and from 10.3% to 9.8%in the El group. Based on these results, it would cost $637 to achieve a 1 percentage point larger decrease in the 10-year probability of CHD for women enrolled in the El. However, because differences between groups were not statistically significant, we cannot reject the hypothesis that the El results in no greater reductions in CHD risk.</p><p><strong>Conclusions: </strong>Although women enrolled in both the MI and El showed decreases in CHD risk during the study period, future research is needed to assess the impact of lifestyle interventions targeting financially disadvantaged women.</p>","PeriodicalId":80044,"journal":{"name":"Journal of women's health & gender-based medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2002-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/152460902760277877","citationCount":"30","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of women's health & gender-based medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/152460902760277877","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 30

Abstract

Objective: The Massachusetts WISEWOMAN Project is a cardiovascular disease (CVD) risk reduction program targeting older uninsured and underinsured women. The cost-effectiveness of providing CVD screening and enhanced lifestyle interventions (EI), compared with providing CVD screening and a minimum intervention (MI), was assessed at five El and six MI healthcare sites.

Methods: Cost calculations were based on data collected during screenings and intervention activities conducted with 1586 women in 1996. Risk factor data, including cholesterol and blood pressure measures, were used to create a summary effectiveness outcome, the 10-year probability of developing coronary heart disease (CHD). The cost-effectiveness ratio of the EI, compared with the MI, was calculated by dividing the incremental cost of the EI by the incremental effectiveness of the EI.

Results: The incremental cost of the EI was $191. During the 1-year study period, the 10-year probability of CHD decreased from 9.4% to 9.2% in the MI group and from 10.3% to 9.8%in the El group. Based on these results, it would cost $637 to achieve a 1 percentage point larger decrease in the 10-year probability of CHD for women enrolled in the El. However, because differences between groups were not statistically significant, we cannot reject the hypothesis that the El results in no greater reductions in CHD risk.

Conclusions: Although women enrolled in both the MI and El showed decreases in CHD risk during the study period, future research is needed to assess the impact of lifestyle interventions targeting financially disadvantaged women.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
针对经济脆弱妇女的心血管疾病风险降低方案的成本效益:马萨诸塞州WISEWOMAN项目。
目的:马萨诸塞州WISEWOMAN项目是一个降低心血管疾病(CVD)风险的项目,目标是老年无保险和保险不足的妇女。与提供CVD筛查和最低干预(MI)相比,提供CVD筛查和增强生活方式干预(EI)的成本效益在5个El和6个MI医疗站点进行了评估。方法:根据1996年对1586名妇女进行筛查和干预活动时收集的数据进行成本计算。危险因素数据,包括胆固醇和血压测量,被用来创建一个总结有效性的结果,即10年发生冠心病(CHD)的概率。与MI相比,EI的成本-效果比是通过EI的增量成本除以EI的增量效果来计算的。结果:EI的增量成本为191美元。在1年的研究期间,MI组的10年冠心病概率从9.4%下降到9.2%,El组从10.3%下降到9.8%。基于这些结果,要使参加El的妇女10年患冠心病的概率降低1个百分点,需要花费637美元。然而,由于两组之间的差异没有统计学意义,我们不能拒绝El不会导致冠心病风险更大降低的假设。结论:虽然在研究期间参加MI和El的妇女都显示冠心病风险降低,但需要进一步的研究来评估针对经济困难妇女的生活方式干预的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Maintaining fairness: who gets funded at NIH, and is the process fair? Entertainment outreach for women's health at CDC. Toward optimal health: the experts discuss polycystic ovary syndrome. Ovarian autoimmune disease and ovarian autoantibodies. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part I.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1